Credit Suisse’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-143,737
| Closed | -$13.9M | – | 4441 |
|
|
2019
Q3 | $13.9M | Sell |
143,737
-33,466
| -19% | -$3.35M | 0.01% | 1127 |
|
|
2019
Q2 | $18.1M | Buy |
177,203
+79,784
| +82% | +$8.61M | 0.02% | 973 |
|
|
2019
Q1 | $11.1M | Buy |
97,419
+66,820
| +218% | +$4.91M | 0.01% | 1178 |
|
|
2018
Q4 | $1.2M | Buy |
30,599
+5,875
| +24% | +$255K | ﹤0.01% | 2643 |
|
|
2018
Q3 | $1.35M | Sell |
24,724
-70,529
| -74% | -$4.82M | ﹤0.01% | 2644 |
|
|
2018
Q2 | $7.88M | Sell |
95,253
-53,193
| -36% | -$4.11M | 0.01% | 1392 |
|
|
2018
Q1 | $9.88M | Buy |
148,446
+5,340
| +4% | +$308K | 0.01% | 1249 |
|
|
2017
Q4 | $7.36M | Buy |
143,106
+75,701
| +112% | +$5.44M | 0.01% | 1488 |
|
|
2017
Q3 | $6.01M | Buy |
67,405
+14,535
| +27% | +$1.1M | 0.01% | 1627 |
|
|
2017
Q2 | $3.16M | Buy |
52,870
+6,696
| +15% | +$374K | ﹤0.01% | 1913 |
|
|
2017
Q1 | $2.46M | Buy |
46,174
+22,697
| +97% | +$1.35M | ﹤0.01% | 2198 |
|
|
2016
Q4 | $1.17M | Sell |
23,477
-2,179
| -8% | -$117K | ﹤0.01% | 2897 |
|
|
2016
Q3 | $1.54M | Buy |
25,656
+3,397
| +15% | +$196K | ﹤0.01% | 2582 |
|
|
2016
Q2 | $1.14M | Sell |
22,259
-1,431
| -6% | -$61.1K | ﹤0.01% | 2815 |
|
|
2016
Q1 | $699K | Buy |
23,690
+7,698
| +48% | +$243K | ﹤0.01% | 2999 |
|
|
2015
Q4 | $724K | Buy |
+15,992
| New | +$838K | ﹤0.01% | 3089 |
|
|
2015
Q3 | – | Sell |
-10,601
| Closed | -$638K | – | 4592 |
|
|
2015
Q2 | $638K | Buy |
10,601
+4,750
| +81% | +$314K | ﹤0.01% | 3538 |
|
|
2015
Q1 | $454K | Buy |
+5,851
| New | +$337K | ﹤0.01% | 3605 |
|
Credit Suisse's ONCE Position: Q4 2019 in Review
Credit Suisse sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 143,737 shares — an estimated $13.9M sold.
Credit Suisse first reported a position in ONCE in Q1 2015 and held it in 18 quarters. The position peaked at $18.1M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Credit Suisse reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Credit Suisse sold 143,737 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $13.9M.
- Credit Suisse first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 18 quarters.
- Credit Suisse's Spark Therapeutics, Inc. Common Stock position peaked at $18.1M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.